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JM	  is	  a	  14-­‐year-­‐old	  female	  admitted	  to	  the	  pediatric	  unit	  on	  a	  72	  hour	  holding	  policy	  after	  
her	  father	  found	  her	  unresponsive	  and	  brought	  her	  to	  hospital.	  After	  regaining	  consciousness,	  
patient	  reports	  taking	  “the	  rest	  of	  the	  bottle”	  of	  Benadryl	  at	  home	  in	  an	  attempt	  to	  “not	  be	  here	  
anymore.”	  JM	  is	  medically	  stable	  by	  the	  following	  morning	  and	  is	  able	  to	  participate	  in	  a	  patient	  
interview.	  She	  reports	  that	  her	  act	  was	  a	  result	  of	  feelings	  of	  abandon	  by	  her	  mother,	  financial	  
difficulties	  facing	  her	  family,	  continual	  teasing	  from	  classmates	  and	  “just	  feeling	  sad.”	  There	  is	  no	  
documented	  family	  depression	  but	  father	  reports	  the	  child	  mother	  “is	  bipolar.”	  She	  is	  not	  taking	  any	  
medications	  currently	  and	  has	  been	  in	  counseling	  at	  her	  school	  for	  the	  last	  6	  months.	  The	  question	  
now	  facing	  her	  care	  team	  becomes	  is	  she	  a	  candidate	  for	  medical	  management	  for	  her	  pediatric	  
depression	  and	  what	  is	  the	  approach	  to	  her	  patient	  specific	  treatment	  plan.	  	  
	   Pediatric	  depression	  is	  an	  increasing	  problem	  facing	  healthcare	  providers	  today	  and	  
knowing	  how	  to	  appropriately	  screen	  and	  treat	  a	  patient	  for	  pediatric	  depression	  is	  something	  new	  
clinicians	  need	  to	  feel	  comfortable	  with.	  The	  following	  is	  a	  guide	  to	  be	  used	  by	  any	  healthcare	  
professional,	  but	  particularly	  pharmacy	  students,	  in	  assisting	  in	  the	  treatment	  and	  management	  of	  
this	  condition.	  	  
• Epidemiology	  and	  Prevalence	  
o <13	  yo	  
 2.8%	  
o 13-­‐18	  yo	  
 5.6%	  
• ~60%	  will	  have	  recurrences	  in	  adulthood	  
• Concern	  for	  increased	  prevalence	  later	  in	  life	  if	  not	  properly	  managed	  in	  childhood	  
o One	  study	  examined	  children	  without	  depression	  who	  were	  9-­‐13	  yo	  >	  than	  7%	  of	  
boys	  and	  almost	  12%	  of	  girls	  developed	  a	  depressive	  disorder	  by	  the	  age	  of	  16	  	  	  
• Risk	  Factors	  	  
o Parental	  depression-­‐	  3	  fold	  	  
o Health	  condition	  (diabetes,	  asthma)	  
o Family	  history	  
o Female	  
o Puberty/Hormonal	  changes	  
o Low	  birth	  weight	  	  
o Maternal	  age	  <18	  
o Obesity	  
o Anxiety/learning	  disorders/sleep	  disorders	  
o Psychological	  risk	  factors	  
o Low	  self	  esteem,	  negative	  body	  image	  	  	  
	  
• Screening	  	  
	  
o Screening	  not	  recommended	  in	  children	  
 Unable	  to	  use	  the	  tools	  we	  have	  available	  due	  to	  lower	  than	  needed	  level	  of	  
cognition	  and	  communication	  
o Recommend	  screening	  in	  primary	  care	  for	  adolescents	  13-­‐18	  yo	  	  
o Several	  options	  for	  screening	  tools	  
 Beck	  Depression	  Inventory	  for	  Primary	  Care	  (BDI)	  
• 12-­‐18	  yo	  
• Self	  report	  
 Children’s	  Depression	  Inventory	  (CDI)	  
• 7-­‐17	  yo	  
• Self	  report,	  parent	  report,	  or	  teacher	  report	  
 Children’s	  Depression	  Rating	  Scale-­‐	  Revised	  (CDRS-­‐R)	  
• 6-­‐12	  yo	  
• Child,	  parent,	  and/or	  teacher	  
• Diagnose	  and	  monitor	  treatment	  response	  
• Most	  commonly	  used	  in	  clinical	  studies	  
o Gold	  standard	  in	  evaluation	  of	  response	  to	  treatment	  in	  clinical	  
trials	  	  
 Multiple	  other	  options	  	  	  
• Diagnosis	  
o Diagnostic	  criteria	  are	  the	  same	  for	  adults	  with	  the	  potential	  for	  a	  different	  
presentation	  outlined	  in	  both	  the	  DSM	  IV	  and	  DSM	  V	  
o Part	  of	  diagnosis	  is	  rule	  out	  of	  other	  potential	  causes,	  differential	  is	  crucial	  
o Must	  assess	  suicide	  risk	  
 Important	  consideration	  for	  treatment	  	  
 Patient	  safety	  is	  our	  number	  one	  concern	  	  	  
	  
• Diagnostic	  Criteria-­‐	  5	  of	  the	  following	  including	  at	  least	  one	  bolded	  option	  
o Must	  be	  present	  for	  a	  2	  week	  period	  and	  represent	  a	  change	  from	  baseline	  
 Depressed	  Mood	  
 Loss	  of	  interest/pleasure	  in	  all/almost	  all	  activities	  
 Significant	  weight	  loss/gain	  or	  appetite	  increase/decrease	  
 Insomnia	  or	  hypersomnia	  
 Psychomotor	  agitation	  or	  retardation	  
 Fatigue/Loss	  of	  energy	  
 Worthlessness/Inappropriate	  guilt	  
 Inability	  to	  concentrate/indecisiveness	  
 Suicidal	  ideation,	  obsession,	  or	  attempt	  
o Different	  presentation	  in	  children-­‐	  important	  to	  distinguish	  
 Children	  may	  present	  with	  more	  of	  an	  activated	  presentation-­‐	  see	  italicized	  
above	  
• Struggle	  to	  make	  decisions	  or	  focus	  for	  a	  significant	  period	  of	  time	  may	  
be	  an	  indicator	  of	  depression	  in	  children	  
o Important	  to	  differentiate	  from	  ADHD	  
• Adolescents	  may	  present	  with	  more	  symptoms	  described	  as	  “bordem”	  
and	  general	  lack	  of	  interest	  	  	  
	  
 Differential	  	  
o Bipolar	  disorder*	  
 Most	  important	  differential	  as	  treatment	  may	  precipitate	  a	  manic	  episode	  in	  
bipolar	  patients	  incorrectly	  treated	  for	  depression	  
o Other	  psychiatric	  disorders	  
o Drug	  of	  abuse	  or	  medication	  
 More	  common	  in	  older	  patients	  	  
o Life	  event	  (ie	  loss	  of	  loved	  one)	  
 May	  precipitate	  a	  major	  depressive	  episode	  needing	  treatment	  but	  initially	  
should	  be	  regarded	  as	  situational	  pending	  further	  evaluation	  	  
o Medical	  condition	  induced	  depression	  
o Cancer,	  hypo/hyperthyroid,	  stroke,	  central	  nervous	  system	  disorder	  
o Medications	  of	  note	  *Key	  place	  for	  pharmacist	  led	  interventions	  
 Antipsychotics	  
 Beta	  Blockers	  
 Contraceptives	  
 Corticosteroids	  	  
 Isotretinoin	  
	  
 Clinical	  Characteristics	  
o Co-­‐morbid	  conditions	  
 Often	  associated	  with	  other	  psychiatric	  disorders	  
 Generalized	  anxiety	  disorder,	  eating	  disorders,	  obsessive	  compulsive	  disorder	  	  	  	  
o Signs	  and	  symptoms	  
 Outlined	  in	  diagnostic	  criteria	  	  
o Laboratory	  values	  
 Not	  of	  much	  value	  in	  diagnosis	  or	  treatment	  	  
o Complications	  
 Risk	  of	  prolonged	  course	  of	  disease,	  decreased	  quality	  of	  life,	  suicide	  attempts	  	  
 Goals	  of	  therapy	  
o Selection	  of	  appropriate	  therapy	  including	  cognitive/psychological	  treatment	  	  	  
o Resolution	  of	  signs	  and	  symptoms	  
o Avoidance	  of	  adverse	  effects	  
o Including	  suicidal	  ideation	  	  
o Long	  term	  remission	  	  
	  
 Non-­‐pharmacologic	  treatment	  	  	  
o Plays	  a	  very	  important	  role	  in	  treatment	  
o Psychotherapy	  should	  always	  be	  a	  component	  of	  childhood	  and	  adolescent	  treatment	  	  
 Stand-­‐alone	  in	  mild	  depression	  
 Medication	  as	  adjunct	  in	  moderate	  to	  severe	  
o Medication	  should	  never	  be	  used	  without	  concurrent	  psychotherapy	  	  	  
 Studies	  overwhelming	  show	  benefit	  to	  this	  combination	  compared	  to	  
medication	  alone	  
o Cognitive	  Behavioral	  Therapy	  (CBT)	  
o Interpersonal	  therapy	  
 Increase	  coping	  skills	  
 NOT	  been	  shown	  to	  be	  more	  effective	  than	  placebo	  in	  children	  	  	  
• Newer	  studies	  may	  indicate	  that	  it	  may	  be	  as	  effective	  as	  CBT	  
	  
 Pharmacologic	  Treatment	  	  
o Potential	  option	  depending	  on	  severity	  and	  history	  
o Indicators	  include:	  
 Prior	  episode	  
 Past	  pharmacologic	  treatment	  
 Family	  history	  w/	  significant	  response	  
 Environmental	  causes	  addressed	  w/	  no	  change	  
 Failed	  psychotherapy	  	  	  
o Cannot	  simply	  use	  data	  in	  adults	  for	  treatment	  of	  children	  
• Neuronal	  pathways	  develop	  as	  we	  age	  
	  
 Pharmacologic	  Treatment	  Options	  
o TCAs	  previously	  used-­‐	  not	  recommended	  
o First	  line	  
 Fluoxetine	  
• Only	  agent	  with	  consistent	  data	  supporting	  a	  decrease	  in	  symptoms	  
• Best	  evidence	  in	  younger	  children	  (2-­‐11)	  
 Citalopram	  
 Sertraline	  
o Other	  options	  
 Escitalopram-­‐	  indication	  for	  treatment	  of	  depression	  in	  children	  ≥	  12	  yo	  
 Venlafaxine	  ER	  
o Lowest	  dose,	  moderate	  titration	  based	  on	  response	  and	  adverse	  effects,	  limited	  
number	  of	  pills	  per	  prescription	  	  
	  
 Agent	  Selection	  	  
o Consider	  all	  relevant	  factors	  
 Co-­‐morbid	  conditions	  
 Patient	  allergies	  or	  drug	  interactions	  
 Cost	  
o As	  in	  adult	  treatment,	  patient	  preference	  plays	  a	  role	  
 Can	  be	  considered/honored	  if	  within	  our	  first	  line	  options	  
 First	  line	  treatments	  should	  still	  be	  first	  line	  
• Patient	  preference	  for	  an	  agent	  that	  is	  not	  proven	  to	  be	  safe	  and	  
effective	  in	  children	  is	  NOT	  a	  	  reason	  to	  use	  that	  agent	  
 Crucial	  to	  assess	  parent	  preference	  as	  well	  
• Compliance	  	  	  
	  
 Fluoxetine-­‐	  Prozac®	  	  
o Approved	  ages:	  depression	  ≥	  8	  yo	  (limited	  data	  in	  2-­‐6	  yo	  for	  anxiety)	  
o Dosing:	  
 Lower	  weight:	  10mg	  PO	  daily,	  can	  increase	  to	  20mg	  daily	  	  after	  several	  	  weeks;	  
max	  is	  20mg	  daily	  	  
 Higher	  weight:	  10-­‐20	  mg	  PO	  daily,	  may	  inc	  to	  20mg	  daily	  	  after	  one	  week;	  max	  
is	  20mg	  daily	  	  	  
• **Have	  seen	  doses	  up	  to	  40mg	  in	  patients	  >	  12	  yo	  	  	  	  	  
o Should	  be	  first	  agent	  considered	  -­‐not	  necessarily	  first	  prescribed	  
 Only	  noted	  agent	  w/	  consistent	  effective	  results	  
 Estimated	  20-­‐40%	  of	  patients	  will	  not	  be	  adequately	  treated	  
o 2D6,	  2C9,	  2C19,	  3A4	  enzyme	  interactions,	  QT	  prolongation,	  anti-­‐platelet,	  SIADH	  	  	  	  
	  
• Fluoxetine	  Efficacy-­‐	  Reported	  Data	  	  
o Fluoxetine	  for	  Acute	  Treatment	  of	  Depression	  in	  Children	  and	  Adolescents	  Study	  	  
 Three	  independent	  diagnostic	  interviews	  using	  two	  evaluation	  tools	  to	  
diagnose	  nonpsychotic	  MDD	  
• Children=	  8	  -­‐	  <13	  and	  adolescents=	  13	  -­‐	  <18	  
 Patients	  assessed	  at	  weeks	  -­‐3,	  -­‐1,	  0,	  1,	  2,	  3,	  5,	  7,	  9	  
 Exclusion:	  serious	  illness	  or	  other	  medical	  complications	  including	  bipolar	  or	  
other	  psychological	  diagnoses	  	  
 Inclusion:	  moderate	  depressive	  symptoms,	  able	  to	  swallow	  whole	  medication	  
without	  difficulty	  	  	  
o Methods	  	  
 Placebo	  controlled,	  single	  blind,	  randomized	  
 Multiple	  academic	  hospitals	  throughout	  the	  US	  
 110	  in	  placebo	  group	  and	  109	  in	  fluoxetine	  group	  
• Week	  1	  treatment=	  10mg	  à	  Week	  2-­‐9=	  20mg	  
 Assess	  by	  trained	  investigators	  each	  week	  starting	  3	  weeks	  before	  treatment	  
was	  initiated	  
 “Remission”	  prospectively	  defined	  as	  endpoint	  Children’s	  Depression	  Rating	  
Scale-­‐	  Revised	  (CDRS-­‐R)	  score	  of	  ≤	  28	  
• A	  score	  of	  30	  is	  the	  cut	  off	  for	  depression	  using	  this	  scale	  	  
o Results	  and	  Conclusions	  	  
 Significantly	  greater	  improvement	  in	  CDRS-­‐R	  scores	  in	  the	  treatment	  group	  
• Defined	  as	  ≥	  30%	  improvement	  in	  symptoms	  
 No	  subgroup	  variations	  in	  results	  
 “Significantly	  more	  fluoxetine-­‐	  treated	  patients	  (41.3%)	  than	  placebo-­‐treated	  
patients	  (19.8%)	  met	  the	  prospectively	  defined	  criteria	  for	  remission	  (p	  <	  
.01)…difference	  in	  the	  percentage	  of	  patients	  responding	  to	  treatment	  
(fluoxetine:	  65.1	  %;	  placebo:	  53.5%)	  was	  not	  significant	  (p	  =	  .093)"	  	  
 Lack	  of	  significant	  results	  with	  other	  scoring	  systems	  	  	  
	  
• Citalopram-­‐Celexa™	  	  
o Approved	  ages:	  Not	  FDA	  approved	  
o Expert	  recommended	  dosing:	  
 Children	  ≤	  11	  
• 10mg/day,	  increase	  by	  5mg/day	  every	  2	  weeks	  as	  needed	  
• Usual	  range	  20-­‐40mg/day	  
 Children	  ≥12	  	  
• 20mg/day,	  increase	  by	  10mg/dayevery	  2	  weeks	  as	  needed	  
• Usual	  range	  20-­‐40mg/day	  	  	  	  	  
o First	  line	  agent	  to	  be	  considered	  after	  fluoxetine	  
o Option	  for	  patients	  who	  failed	  first	  agent	  or	  have	  initial	  aversion	  to	  fluoxetine	  
o Similar	  interaction	  profile	  to	  fluoxetine;	  3A4,	  2C9,	  2C19,	  QT	  prolongation,	  anti-­‐
platelet,	  SIADH	  	  
	  
• Sertraline-­‐Zoloft®	  	  
o Approved	  ages:	  Not	  FDA	  approved,	  data	  for	  children	  6-­‐12	  yo	  	  
 Expert	  recommended	  dosing:	  12.5-­‐25mg	  daily	  ,	  can	  increase	  by	  25-­‐50mg/day	  
at	  a	  minimum	  of	  7	  day	  intervals;	  typical	  dose	  is	  around	  1.6mg/kg/day	  at	  a	  
range	  of	  25-­‐200	  mg/day;	  max	  20omg/day	  
o Pediatric	  patients	  have	  a	  higher	  metabolism	  of	  sertraline-­‐	  lower	  doses	  are	  still	  
recommended	  
o Drug	  interactions:	  2C8,	  2D6,	  3A4,	  1A2,	  QT	  prolongation,	  anti-­‐platelet,	  SIADH	  	  	  	  	  	  	  
	  
• Escitalopram-­‐	  Lexapro®	  	  
o Possible	  agent	  in	  resistant	  depression	  
 Least	  data	  available	  in	  pediatric	  population	  
o One	  RCT	  done	  in	  2006	  
 Did	  NOT	  demonstrate	  significant	  results	  when	  compared	  to	  placebo	  	  
o More	  acceptable	  in	  older	  pediatric	  patients	  
 Post-­‐hoc	  analysis	  of	  adolescents	  (12-­‐17)	  in	  2006	  trial	  did	  show	  significant	  
improvement	  in	  CDRS-­‐R	  
o No	  significant	  side	  effects	  noted-­‐	  headache	  and	  abdominal	  pain	  most	  common	  
 Suicidal	  ideation	  still	  an	  issue	  	  	  	  
o Further	  testing	  needed	  
o Similar	  drug	  interaction	  profile	  	  	  	  
	  
 Venlafaxine	  ER-­‐	  Effexor	  XR®	  	  
o Two	  RCTs	  to	  date	  	  
o No	  statistical	  significant	  differences	  in	  CDRS-­‐R	  scores	  between	  venlafaxine	  ER	  and	  
placebo	  in	  either	  study	  
 Possible	  benefit	  in	  adolescents	  (12-­‐17)	  but	  no	  benefit	  seen	  with	  children	  (7-­‐
11)	  
 Not	  studied	  in	  children	  younger	  than	  7	  
o Anorexia	  and	  abdominal	  pain	  most	  commonly	  reported	  side	  effects	  
o Hostility	  and	  suicide-­‐related	  events	  were	  seen	  in	  the	  treatment	  groups	  in	  comparison	  
to	  the	  placebo	  group	  
o Reserved	  for	  patients	  who	  fail	  fluoxetine	  and	  sertraline	  
 Dosing:	  37.5	  mg/day	  x	  1	  week	  à	  75	  mg/day	  
• Have	  also	  seen	  higher	  doses	  in	  combination	  with	  lithium	  	  	  	  
	  
 Other	  Options-­‐	  FYI-­‐	  Not	  recommended	  or	  proven	  to	  be	  effective	  
o Desvenlafaxine-­‐	  Pristiq*	  
 *No	  generic	  available	  	  
o Duloxitine-­‐	  Cymbalta	  
o Mirtazapine-­‐	  Remeron	  
o Bupropion-­‐	  Wellbutrin	  
o TCAs	  
 Actually	  proven	  to	  be	  unsafe	  and	  ineffective	  
• Treatment	  Failure	  and	  Duration	  	  
o Two	  different	  schools	  of	  thought	  in	  treatment	  duration	  
 Guidelines	  dictate	  a	  duration	  of	  8-­‐12	  weeks	  before	  terming	  a	  specific	  
treatment	  as	  a	  failure	  	  
 Newer	  data	  suggest	  that	  a	  more	  aggressive	  approach	  of	  only	  allowing	  4-­‐6	  
weeks	  before	  calling	  treatment	  with	  no	  change	  failure	  and	  attempting	  to	  
change	  or	  modify	  treatment	  
o If	  patient	  fails	  treatment	  with	  a	  first	  line	  agent,	  switch	  to	  another	  first	  line	  	  
o If	  patient	  fails	  all	  first	  line	  -­‐	  psychiatric	  consult	  
o Multiple	  agents	  NOT	  indicated	  in	  children	  	  
 Can	  be	  used	  in	  treatment	  resistant	  depression	  but	  this	  should	  be	  under	  the	  
care	  of	  a	  trained	  specialist	  
o Treatment	  should	  continue	  for	  at	  least	  4-­‐6	  months	  after	  remission	  	  
 Does	  NOT	  have	  to	  be	  lifelone	  
 Should	  be	  warned	  about	  the	  risk	  of	  relapse	  and	  need	  for	  re-­‐treatment	  	  
	  
• Disease	  State	  Monitoring	  
o Close	  monitoring	  in	  all	  cases	  
 Black	  box	  warning	  for	  increased	  suicide	  risk	  
 This	  population	  is	  particularly	  vulnerable	  
• Weekly	  phone	  monitoring,	  regular	  visits	  to	  provider	  
o SSRI-­‐	  associated	  behavioral	  activation	  
 Restlessness,	  hyperkinesis,	  agitation,	  hyperactivity	  
 2-­‐3	  times	  more	  prevalent	  in	  children	  
 May	  be	  able	  to	  decrease	  risk	  with	  slower	  titration	  schedules	  (q	  2-­‐4	  weeks)	  
o Monitor	  weight	  and	  growth	  –	  concern	  for	  weight	  loss	  due	  to	  decreased	  appetite	  	  	  	  
	  
• Suicidal	  Ideation	  	  
o Clinical	  Response	  and	  Risk	  for	  Reported	  Suicidal	  Ideation	  in	  Pediatric	  Antidepressant	  
Treatment	  
o Meta-­‐analysis	  of	  RCTs	  
 15	  MDD	  (2910	  participants),	  6	  OCD,	  6	  Non-­‐OCD	  anxiety	  from	  1988	  to	  2006	  
 Increased	  risk	  for	  suicidal	  ideation	  or	  attempt	  	  
• Applies	  to	  all	  trials	  for	  all	  indications	  
• Highest	  rate	  of	  suicidality	  	  in	  placebo	  group	  w/	  MDD	  trials	  	  
 Overall	  NNH	  was	  143,	  MDD	  NNH	  112	  
• Pooled	  risk	  of	  suicidal	  ideation/attempt	  in	  MDD	  trials	  was	  3%	  in	  
treatment	  vs.	  2%	  in	  placebo	  (p=0.08)	  resulting	  in	  a	  difference	  of	  1%	  
 NNT	  was	  10	  for	  MDD	  (OCD=6,	  Non-­‐OCD=3)	  
• While	  it	  was	  not	  significant,	  the	  highest	  risk	  and	  most	  modest	  benefit	  
was	  in	  MDD	  trials	  
o Study	  Conclusions	  
 Despite	  the	  increased	  risk,	  the	  risk	  vs.	  benefit	  picture	  is	  clearly	  in	  favor	  of	  the	  
use	  of	  antidepressants	  in	  certain	  cases	  
o Considerations:	  
 The	  trials	  included	  SSRIs	  and	  second	  generation	  agents	  
 The	  average	  length	  of	  a	  trial	  was	  8	  weeks	  for	  major	  depressive	  disorder	  (MDD)	  
 Most	  studies	  were	  multicenter;	  median	  number	  of	  cites	  was	  21	  	  
 For	  MDD	  trials,	  CDRS-­‐R	  was	  used	  in	  11/15	  and	  CGI-­‐I	  for	  response	  in	  8/15	  	  
	  
• Pediatric	  Medication	  Monitoring	  	  
 Do	  NOT	  abruptly	  discontinue	  treatment	  
 Certain	  side	  effect	  are	  more	  common	  in	  children	  than	  adults:	  
• Other	  potential	  side	  effects	  
• GI	  upset,	  HA,	  nervousness,	  restlessness,	  weight	  loss,	  rash,	  SIADH,	  bone	  
fractures,	  CNS	  depression	  	  
	  
In	  the	  case	  of	  JM,	  the	  physicians	  ruled	  her	  depression	  to	  be	  situational	  and	  decided	  it	  would	  
be	  best	  that	  the	  patient	  not	  be	  placed	  on	  pharmacologic	  therapy	  but	  instead	  received	  continued	  
counseling	  and	  close	  follow-­‐up.	  As	  a	  new	  clinician,	  I	  do	  not	  necessarily	  agree	  with	  the	  designed	  care	  
plan	  as	  I	  believe	  a	  suicide	  attempt	  after	  6	  months	  of	  CBT	  should	  be	  considered	  treatment	  failure	  and	  
JM	  should	  be	  evaluated	  as	  a	  candidate	  for	  medical	  management,	  possibly	  with	  fluoxetine.	  However,	  
much	  of	  pediatric	  medicine	  falls	  into	  a	  grey	  area	  and	  that	  is	  certainly	  the	  case	  for	  this	  particular	  
patient.	  	  	  	  
Adequate	  treatment	  of	  pediatric	  depression	  is	  crucial	  to	  prevent	  adverse	  events	  later	  in	  life.	  
When	  looking	  at	  an	  overall	  treatment	  course	  for	  a	  patient,	  cognitive	  therapy	  is	  always	  first	  line	  and	  
pharmacologic	  treatment	  is	  not	  appropriate	  in	  all	  cases.	  However,	  if	  pharmacologic	  treatment	  is	  
needed,	  fluoxetine	  is	  considered	  first	  line	  and	  the	  first	  agent	  that	  should	  be	  considered.	  Anytime	  
medication	  is	  initiated,	  it	  should	  be	  in	  combination	  with	  cognitive	  therapy	  as	  this	  has	  been	  proven	  
to	  be	  more	  effective	  than	  medication	  alone.	  Close	  monitoring	  is	  required	  in	  all	  cases	  and	  parents	  
should	  be	  warned	  about	  suicidal	  ideation	  in	  a	  frank	  manner	  that	  will	  ensure	  everyone	  knows	  how	  
to	  best	  keep	  the	  child	  safe.	  Pediatric	  depression	  is	  a	  challenging	  disease	  state	  but	  basing	  treatment	  
in	  evidenced	  based	  medicine	  and	  providing	  patient	  centered	  care	  can	  allow	  these	  children	  to	  go	  on	  
to	  lead	  happy,	  healthy	  lives.	  	  
	  
-­‐A	  large	  part	  of	  this	  project	  for	  me	  was	  developing	  a	  lecture	  on	  this	  subject	  to	  teach	  to	  my	  
classmates	  in	  order	  to	  prepare	  them	  to	  treat	  pediatric	  depression	  as	  clinicians	  in	  the	  future.	  In	  
addition,	  I	  created	  the	  above,	  abbreviated	  and	  easy	  to	  use	  in	  practice	  guide	  to	  assist	  them	  in	  their	  
clinical	  management	  in	  the	  future,	  as	  well	  as	  an	  assessment	  given	  at	  the	  conclusion	  of	  the	  lecture	  to	  
ensure	  all	  important	  points	  were	  adequately	  covered.	  As	  this	  encompassed	  both	  my	  interest	  in	  
pediatrics	  and	  academia,	  I	  was	  able	  to	  gain	  insights	  about	  this	  particular	  disease	  state,	  as	  well	  as	  the	  
requirements	  to	  successfully	  lecture	  over	  a	  topic	  in	  a	  way	  that	  will	  assist	  future	  clinicians	  in	  the	  
management	  of	  their	  patients.	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